阿托伐他汀对不稳定型心绞痛患者介入术后高敏C反应蛋白及白细胞介素6的影响

Effect of atorvastatin on high-sensitivity C-reactive protein and interleukin-6 in unstable angina pectoris patients after intervention

目的探讨阿托伐他汀对不稳定型心绞痛（UAP）患者介入术后高敏c反应蛋白（hs-CRP）及白细胞介素6（IL-6）的影响。方法选择80例UAP患者，均行经皮冠状动脉介入治疗（PCI），术后按照随机数字表法分为A组和B组，每组40例。A组患者在常规心内科治疗措施基础上给予阿托伐他汀20mg治疗；B组在常规心内科治疗措施基础上给予阿托伐他汀40mg治疗。分别于术前、术后24h、术后3周抽血检测患者血清hs．CRP及IL-6水平，并进行比较。结果术前A组和B组患者血清hs-CRP及IL-6水平比较差异无统计学意义[（5．6±1．2）mg／L比（5．6±1．1）mg／L和（211．9±21．2）ng／L比（209．6±19．9）ng/L，P〉0．05]；术后24hA组和B组患者血清hs-CRP及IL．6水平均较术前显著增高，差异有统计学意义（P〈0．05），但A组和B组比较差异无统计学意义[（8．1±1．1）mg／L比（8．5±1．2）mg／L和（311．1±20．9）ng／L比（313．3±18．5）ng／L，P〉0．05]；术后3周A组和B组患者血清hs．CRP及IL-6水平均较术前显著下降，差异有统计学意义（P〈0．05），A组和B组比较差异亦有统计学意义[（3．1±1．1）mg／L比（1．9±0．8）mg／L和（163．3±18．5）ng／L比（123．3±19．5）ng／L，P〈0．05]，术后A组和B组患者均未出现明显的不良反应，肝功能均未见明显异常。结论行PCI的UAP患者术后给予阿托伐他汀治疗可以明显降低患者血清hs－CRP和IL-6水平，且40mg较20mg治疗效果更明显，值得临床推广应用。

Objective To explore the effect of atorvastatin on high-sensitivity C-reactive protein （hs-CRP） and interleukin-6 （IL-6） in unstable angina pectoris（UAP） patients after intervention. Methods Eighty cases with UAP who underwent pereutaneous coronary intervention （PCI） were divided into group A and group B by random digits table method with 40 cases each after PCI. The patients in group A were given regular heart treatment and atorvastatin 20 mg treatment. The patients in group B were given regular heart treatment and atorvastatin 40 mg treatment. The serum hs-CRP and IL-6 was determined before treatment and 24 h, 3 weeks after treatment and compared between two groups. Results There was no significant difference in the serum hs-CRP and IL-6 before treatment between group A and group B [ （5.6 ＋ 1.2 ） mg/L vs.（5.6 ~ 1.1） mg/L and （211.9± 21.2） ng/L vs.（209.6± 19.9） ng/L,P〉 0.05]. The serum hs-CRP and IL-6 24 h after treatment in group A and group B were increased compared with that before treatment, and there was significant difference （P 〈 0.05 ）, but there was no significant difference between group A and group B[（8.1 ±1.1） mg/L vs. （8.5 ± 1.2） mg/L and （311.1 ±20.9） ng/L vs. （313.3± 18.5） ng/L,P〉0.05]. The serum hs-CRP and IL-6 3 weeks after treatment in group A and group B were decreased compared with that before treatment, there were significant difference （P 〈 0.05）, and there were significant difference between group A and group B [ （3.1 ＋ 1.1 ） mg/L vs. （ 1.9 ＋ 0.8） mg/L and （ 163.3 ~ 18.5） ng/L vs. （ 123.3 ＋ t 9.5 ） ng/L,P 〈 0.05 ]. No obvious adverse reaction was observed in two groups after treatment and liver function was not seen obvious anomaly. Conclusions Atorvastatin treatment in UAP patients after PCI can significantly reduce the serum hs-CRP and IL-6, and the 40 mg treatment is better than the 20 mg treatment. It is worth of clinical application.